Piper Jaffray is upping the price target on Biovail Corporation (NYSE: BVF) to $35 from $30, and maintaining its Overweight rating on strong free cash flow numbers. In the research note to clients ...
LocalizedUSA Valeant Pharmaceuticals International Inc., formerly Biovail Corporation, is a specialty pharmaceutical company. The Company focuses on developing and commercializing products in specialty central nervous system (CNS) disorders. As of December 31, ...